Kiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) will be posting its quarterly earnings results before the market opens on Tuesday, April 23rd. Analysts expect Kiniksa Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.15. The company had revenue of $83.40 million for the quarter, compared to the consensus estimate of $72.31 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. On average, analysts expect Kiniksa Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA traded down $0.51 during trading on Wednesday, reaching $16.95. The company had a trading volume of 389,307 shares, compared to its average volume of 400,750. The stock's fifty day moving average price is $19.61 and its 200 day moving average price is $17.97. Kiniksa Pharmaceuticals has a fifty-two week low of $10.65 and a fifty-two week high of $22.09. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of 94.17 and a beta of 0.27.

Insider Buying and Selling

In other news, CAO Michael R. Megna sold 5,126 shares of the company's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total transaction of $111,695.54. Following the transaction, the chief accounting officer now directly owns 17,588 shares of the company's stock, valued at approximately $383,242.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CAO Michael R. Megna sold 5,126 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company's stock, valued at $383,242.52. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Sanj K. Patel sold 12,742 shares of the firm's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now owns 70,594 shares of the company's stock, valued at approximately $1,517,065.06. The disclosure for this sale can be found here. Insiders have sold 33,109 shares of company stock valued at $709,929 over the last quarter. Company insiders own 54.23% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at $60,000. Royal Bank of Canada lifted its position in shares of Kiniksa Pharmaceuticals by 44.2% in the second quarter. Royal Bank of Canada now owns 3,523 shares of the company's stock valued at $50,000 after acquiring an additional 1,080 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at $59,000. Tower Research Capital LLC TRC increased its position in Kiniksa Pharmaceuticals by 437.7% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,915 shares of the company's stock worth $53,000 after purchasing an additional 4,001 shares in the last quarter. Finally, State of Wyoming raised its stake in Kiniksa Pharmaceuticals by 41.1% in the 4th quarter. State of Wyoming now owns 7,160 shares of the company's stock valued at $107,000 after purchasing an additional 2,087 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KNSA. Wedbush restated an "outperform" rating and issued a $30.00 target price (up previously from $28.00) on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, April 2nd. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.